Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4331272 | 1.00 | ADRB2 (0.50) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL30234873 | 1.00 | ADRB2 (0.50) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL3063193 | 1.00 | ADRB2 (0.50) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| Water SCHEMBL9888404 | 0.98 | ADRB2 (0.49) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL7761635 | 0.93 | ADRB2 (0.46) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL22639009 | 0.86 | KMT2A (0.47) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL777261 | 0.84 | NPC1 (0.53) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL29436920 | 0.84 | NPC1 (0.53) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL8193958 | 0.80 | ADRB2 (0.47) | ADRB2ADRB1ADRB3TSHRKMT2A | |
| SCHEMBL10004127 | 0.80 | NPC1 (0.50) | ADRB2ADRB1ADRB3TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352512-A2 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-11-20 | — | — | US | claimed |
| US-20250352513-A2 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-11-20 | — | — | US | claimed |
| US-20250214934-A1 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-07-03 | — | — | US | claimed |
| US-20250205197-A1 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-06-26 | — | — | US | claimed |
| EP-4493543-A1 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-01-22 | — | — | EP | claimed |
| EP-4493544-A1 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2025-01-22 | — | — | EP | claimed |
| WO-2023173229-A1 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-09-21 | — | — | WO | claimed |
| WO-2023173227-A1 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | Enveric Biosciences Canada Inc. (CA) | 2023-09-21 | — | — | WO | claimed |
| EP-3710437-B1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER OF LOW OPTICAL PURITY | SIEGFRIED AG (CH) | 2022-12-14 | — | — | EP | claimed |
| US-11279685-B2 | Enantiomeric separation of racemic nicotine by addition of an O,O″-disubstituted tartaric acid enantiomer | SIEGFRIED AG (CH) | 2022-03-22 | — | — | US | claimed |
| US-20200331883-A1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER | SIEGFRIED AG (CH) | 2020-10-22 | — | — | US | claimed |
| EP-3710437-A1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER | Siegfried AG (CH) | 2020-09-23 | — | — | EP | claimed |
| CN-104193792-B | A kind of technique preparing ursodesoxycholic acid | HARBIN INSTITUTE OF TECHNOLOGY (CN) | 2015-12-02 | — | — | CN | claimed |
| CN-104193792-A | Process for preparing deoxycholic acid | HARBIN INST OF TECHNOLOGY | 2014-12-10 | — | — | CN | claimed |
| US-7718796-B2 | Process for the preparation of caprolactam CGRP antagonist | MERCK SHARP & DOHME CORP. (US) | 2010-05-18 | — | — | US | claimed |
| US-20090124799-A1 | Process for the preparation of Caprolactam Cgrp Antagonist | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | claimed |
| US-7164025-B2 | Manufacture of single isomer methylphenidate | CELLTECH PHARMA EUROPE LIMITED (GB) | 2007-01-16 | — | — | US | claimed |
| US-20020032335-A1 | Manufacture of single isomer methylphenidate | CELLTECH PHARMA EUROPE LIMITED (GB) | 2002-03-14 | — | — | US | claimed |
| EP-4223293-B1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INST OF GERONTOLOGY (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-4089861-A | NEUROLEPTIC AGENT | HOFFMANN-LA ROCHE, INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352512-A2 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, HTR2C, HTR3C | ADRB2 753/4885ADRB1 1252/4885ADRB3 369/4885 |
| US-20200331883-A1 | ENANTIOMERIC SEPARATION OF RACEMIC NICOTINE BY ADDITION OF AN O,O'-DISUBSTITUTED TARTARIC ACID ENANTIOMER | CHRNB1, CHRNA1, CHRM1 | ADRB2 108/4885ADRB1 28/4885ADRB3 160/4885 |
| US-20250214934-A1 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, HTR2C, HTR3C | ADRB2 753/4885ADRB1 1252/4885ADRB3 369/4885 |
| US-11279685-B2 | Enantiomeric separation of racemic nicotine by addition of an O,O″-disubstituted tartaric acid enantiomer | CHRNB1, CHRNA1, CHRM1 | ADRB2 101/4885ADRB1 27/4885ADRB3 153/4885 |
| US-20250205197-A1 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | SLC6A4, HTR2B, SLC6A3 | ADRB2 388/4885ADRB1 303/4885ADRB3 176/4885 |
| US-20090124799-A1 | Process for the preparation of Caprolactam Cgrp Antagonist | CALCRL, CALCR, CALCA | ADRB2 209/4885ADRB1 173/4885ADRB3 303/4885 |
| US-20250352513-A2 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | SLC6A4, HTR4, SLC6A3 | ADRB2 1331/4885ADRB1 1396/4885ADRB3 614/4885 |
| US-20020032335-A1 | Manufacture of single isomer methylphenidate | COMT, CYP2D6, METTL3 | ADRB2 84/4885ADRB1 31/4885ADRB3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.